Search clinical trials for: Autologous Chimeric Antigen Receptor (CAR) T Cells

Total 495349 results

Medical College of Wisconsin

Recruiting

Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma (EMBRACE)

Refractory Multiple Myeloma | Relapse Multiple Myeloma

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor

Hepatocellular Carcinoma | Non-small Cell Lung Cancer | Pancreatic Carcinoma | Triple-Negative Invasive Breast Carcinoma

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

Solid Tumor | Liposarcoma | Rhabdomyosarcoma | Wilms Tumor | Malignant Rhabdoid Tumor | Yolk Sac Tumor | Liver Cell Carcinoma | Embryonal Sarcoma of the Liver

United States
Baylor College of Medicine
National Cancer Institute (NCI); Stand Up To Cancer; Center for Cell and Gene... and other collaborators

Recruiting

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Sarcoma | Soft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma | Rhabdomyosarcoma | Synovial Sarcoma | HER-2 Protein Overexpression | Undifferentiated Sarcoma

United States
University of Alberta
Alberta Cancer Foundation; Canadian Cancer Trials Group

Recruiting

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002)

Relapsed Non Hodgkin Lymphoma | Relapsed Pediatric ALL | Relapsed Adult ALL

Canada
Southwest Hospital, China

Unknown

the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
KK Women's and Children's Hospital
National University Hospital, Singapore; Singapore General Hospital

Recruiting

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

Lymphoblastic Leukemia, Acute, Childhood | Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR

Singapore
Kite, A Gilead Company

Terminated

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Multiple Myeloma | Ovarian Cancer | Fallopian Tube Cancer | Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma

United States
Peking Union Medical College Hospital
Cellular Biomedicine Group Ltd.

Completed

A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

B-cell Non-Hodgkin Lymphoma

China
First Affiliated Hospital of Harbin Medical University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.

Pancreatic Cancer | CAR

China
Chinese PLA General Hospital

Unknown

CART-19 Immunotherapy in Mantle Cell Lymphoma

Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Non-hodgkin Lymphoma,B Cell

China
Institute of Hematology and Blood Transfusion,...

Recruiting

CART19 Cells Effects in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma (UHKT-CAR19-01)

Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Czechia
Chimeric Therapeutics

Recruiting

CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Glioblastoma Multiforme of Brain

United States
Ruijin Hospital

Recruiting

Axi-cel Retreatment in Relapsed/Refractory LBCL

CAR-T Retreatment

China
Xijing Hospital

Unknown

CD147-CART Cells in Patients With Recurrent Malignant Glioma.

Recurrent Glioblastoma | CD147 Positive

China
Hideho Okada, MD, PhD
National Cancer Institute (NCI); California Institute for Regenerative Medicine...

Recruiting

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Glioblastoma | Recurrent Glioblastoma | EGFR Gene Mutation | MGMT-Unmethylated Glioblastoma

United States
Sheba Medical Center

Recruiting

CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression

Acute Myeloid Leukemia

Israel
Jazz Pharmaceuticals

Terminated

A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity

Neurotoxicity Syndromes | DLBCL

United States
Peter MacCallum Cancer Centre, Australia

Completed

A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours (LeY-CAR-T)

Advanced Cancer

Australia
Chongqing Public Health Medical Center
Zhejiang Qixin Biotech; Chongqing Sidemu Biotech

Unknown

A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19

COVID-19

China
Bioray Laboratories
Changhai Hospital

Suspended

LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer

Castrate-Resistant Prostate Cancer

China
University College, London

Active, not recruiting

A New Study Evaluating the Activity of Modular CAR T for mYeloma (MCARTY)

Multiple Myeloma

United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

Platinum-Resistant Ovarian Carcinoma

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent... and other conditions

United States
Bioray Laboratories
First Affiliated Hospital of Zhejiang University

Completed

PD1-CD19-CART in Patients With r/r B-cell Lymphoma

B-cell Lymphoma

China
Zhejiang University
Bioray Laboratories

Completed

PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer

Castrate-Resistant Prostate Cancer

China
Peking University
CARsgen Therapeutics Co., Ltd.

Completed

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Advanced Solid Tumor

China
Ruijin Hospital
UTC Therapeutics Inc.

Recruiting

Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors (Amaretto)

Refractory Malignant Solid Neoplasm

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Multiple Myeloma | New Diagnosis Tumor

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Southwest Hospital, China

Recruiting

A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Lymphoma | Leukemia

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma

Lymphoma

China
Chongqing Precision Biotech Co., Ltd
Shanxi Bethune Hospital

Recruiting

CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors

Breast Cancer | Gastric Cancer | Esophageal Cancer | Lung Cancer | Rectal Cancer | Colon Cancer | Pancreas Cancer

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

Acute Myeloid Leukemia | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Extranodal NK/T-cell Lymphoma, Nasal Type | T-cell Prolymphocytic Leukemia | T-cell Large Granular Lymphocytic Leukemia | Peripheral T-cell Lymphoma, NOS | Enteropathy-type Intestinal T-cell Lymphoma

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaborators

Recruiting

4SCAR-T Therapy Post CD19-targeted Immunotherapy

CD19 Negative B-cell Malignancies

China
CAR-T (Shanghai) Biotechnology Co., Ltd.

Not yet recruiting

Clinical Study on the Safety and Efficacy of Dental Pulp Mesenchymal Cells in the Treatment of Depression

Depression
CAR-T (Shanghai) Biotechnology Co., Ltd.

Unknown

Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells

COVID-19
CAR-T (Shanghai) Biotechnology Co., Ltd.

Unknown

Clinical Study of Pulp Mesenchymal Stem Cells in the Treatment of Primary Mild to Moderate Knee Osteoarthritis

Knee Osteoarthritis

China
CAR-T (Shanghai) Biotechnology Co., Ltd.

Unknown

Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet Function

Type1diabetes

China
Peking University People's Hospital

Not yet recruiting

CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

T-cell Non-Hodgkin's Lymphoma
Beijing Boren Hospital

Recruiting

Study of Anti-CD22 CAR-T Cells Treating Leukemia Children

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia

China
Chinese PLA General Hospital

Unknown

A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

B Cell Lymphoma | B Cell Leukemia

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaborators

Recruiting

PSMA-specific CAR-T Cell Therapy

PSMA Positive Tumors or Tumor Tissues

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL

B-Cell Acute Lymphoblastic Leukemia, Adult

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Recruiting

CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Acute Lymphoblastic Leukemia With Failed Remission

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei Hospital

Recruiting

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Lymphoma | Leukemia | Multiple Myeloma of Bone (Diagnosis)

China
Vor Biopharma

Recruiting

Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Leukemia, Myeloid, Acute

United States
Baylor College of Medicine
Cancer Prevention Research Institute of Texas; Center for Cell and Gene Therapy... and other collaborators

Active, not recruiting

Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP)

Liver Cancer

United States
Zhejiang University
CARsgen Therapeutics Co., Ltd.

Completed

4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3

Advanced Hepatocellular Carcinoma

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA)

T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | T-non-Hodgkin Lymphoma

United States

Search clinical trials for: Autologous Chimeric Antigen Receptor (CAR) T Cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations